Search hospitals

>

California

>

Torrance

Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center

Claim this profile

Torrance, California 90502

Global Leader in Cancer

Conducts research for Brain Tumor

Conducts research for Non-Hodgkin's Lymphoma

Conducts research for Solid Tumors

Conducts research for Brain Cancer

103 reported clinical trials

8 medical researchers

Photo of Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center in TorrancePhoto of Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center in Torrance

Summary

Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center is a medical facility located in Torrance, California. This center is recognized for care of Cancer, Brain Tumor, Non-Hodgkin's Lymphoma, Solid Tumors, Brain Cancer and other specialties. Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center is involved with conducting 103 clinical trials across 317 conditions. There are 8 research doctors associated with this hospital, such as Eduard H. Panosyan, George A Karpouzas, MD, William French, MD, and Loren G Miller.

Area of expertise

1

Cancer

Global Leader

Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center has run 15 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage II
2

Brain Tumor

Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center has run 9 trials for Brain Tumor. Some of their research focus areas include:

Stage IV
Stage I
Stage II

Top PIs

Clinical Trials running at Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center

Cancer

Testicular cancer

Type 2 Diabetes

Cardiovascular Disease

Ovarian Carcinoma

Ovarian Tumors

Testicular Carcinoma

Ovarian Choriocarcinoma

Myelofibrosis

Stroke

Image of trial facility.

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.

Recruiting

2 awards

Phase 3

26 criteria

Image of trial facility.

LY3537982 + Immunotherapy/Chemotherapy

for Non-Small Cell Lung Cancer

This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.

Recruiting

1 award

Phase 3

14 criteria

Image of trial facility.

Health Information Collection

for Childhood Cancer

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

Recruiting

1 award

N/A

10 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center?